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Abstract  (250  words):  39	  
  40	  
Background:   Timely   access   to   comprehensive   specialist   care   is   crucial   in  41	  
Juvenile   Systemic   Lupus   Erythematosus   (JSLE)   with   barriers   in   access   to  42	  
specialist  care  having   the  potential   to  negatively   influence  disease   trajectory  43	  
and   outcomes.   Objectives:   To   investigate   factors   that   may   influence   the  44	  
interval  between  symptom-­onset  and  JSLE  diagnosis.  Methods:  Data  from  all  45	  
patients   recruited   to   the   UK   JSLE   Cohort   Study   between   2006-­2011   and  46	  
meeting   American   College   of   Rheumatology   (ACR)   criteria   for   lupus   were  47	  
analysed.   Variables   associated   with   time   between   symptom-­onset   and  48	  
diagnosis  were   identified  using  correlation  tests.  Linear  regression  was  used  49	  
to   identify   independent   predictors   of   access   to   care.  Results:   Two  hundred  50	  
and  fifty  seven  children  with  JSLE  were  included  in  the  analysis  (216  females,  51	  
41  males,  ratio  5.3:1).  Median  time  from  symptom-­onset  to  diagnosis  was  0.4  52	  
years   (range   0.0-­14.1   years,   inter-­quartile   range   [IQR]   0.2-­1.4).   A   linear  53	  
regression   model   identified   being   of   African   or   Caribbean   origin   (p=0.006),  54	  
Asian   (p=0.045),   referred   by   a   paediatrician   (p=0.047)   or   having   nephritis  55	  
(p=0.045)   at   presentation,   as   independent   predictors   of   shorter   time   to  56	  
diagnosis.   Being   of   Caribbean   or   Asian   origin,   compared   to   white,   was  57	  
associated   with   a   56%   and   37%   reduction   in   geometric   mean   time   to  58	  
diagnosis  respectively.  Similarly,  being  referred  to  paediatric  rheumatology  by  59	  
a  paediatrician  or  having  nephritis  at  presentation,  was  also  associated  with  a  60	  
32%   and   36%   reduction   in   geometric   mean   time   to   diagnosis   respectively.  61	  
Conclusion:   Within   this   national   UK   cohort,   ethnic   origin,   initial   source   of  62	  
referral  and  having   lupus  nephritis  at  presentation,  were  strong  predictors  of  63	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the  interval  to  establishing  a  diagnosis  of  JSLE.    64	  
  65	  
Background:    66	  
  67	  
Delays   in  diagnosis  and   initial   access   to   specialist   care  are  well   reported   in  68	  
Juvenile   Idiopathic  Arthritis   (JIA),  Rheumatoid  Arthritis   (RA)   [1,   2]   and   have  69	  
been   reported   in   Juvenile-­onset   Systemic   Lupus   Erythematosus   (JSLE)   [3].  70	  
Diagnosis   in   JSLE   can   be   challenging   as   the   condition   often   presents   with  71	  
non-­specific   symptoms,   such   as   fatigue,   arthralgia,   mouth   ulcers   and  72	  
headaches,   occurring   intermittently   and   cumulatively   over   many   months.  73	  
Conversely,   presentation   can   be   acute   with   potentially   life-­threatening  74	  
manifestations  e.g.  renal  failure  or  seizures.  Major  organ  involvement  is  more  75	  
prevalent  in  JSLE  than  in  adult-­onset  SLE  with  more  rapid  accrual  of  disease  76	  
related  damage  [3-­5].  There   is  no  single  diagnostic   test  and  diagnosis  relies  77	  
upon   awareness   and   experience,   comprehensive   clinical   assessment,  78	  
judicious   interpretation   of   investigations   and   often   exclusion   of   other  79	  
conditions  such  as  malignancy.    80	  
  81	  
In   both   RA   and   JIA,   reducing   the   time   from   diagnosis   to   starting   disease  82	  
modifying   anti-­rheumatic   drugs   is   important   in   optimising   outcomes   [6,   7].  83	  
Otten   et   al   recently   investigated   the   relationship   between   disease   activity  84	  
patterns  and  early  aggressive   treatment   in  JSLE.  Patients  who  were   treated  85	  
aggressively   at   an   early   stage   (within   6  months)   subsequently   had   a  more  86	  
favorable   disease   course   (longer   quiescence  pattern),   compared   to   patients  87	  
who  were   not   treated   aggressively   early   (chronically   active   disease  pattern)  88	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[8].    89	  
  90	  
There   is  a  marked  paucity  of  previous  studies  exploring  access   to  specialist  91	  
care  in  JSLE  when  compared  to  JIA,  RA  and  SLE  [2,  6,  7,  9,  10].  The  Euro-­92	  
Lupus   cohort,   including   1000   patients   (76   with   JSLE)   from   7   European  93	  
countries  has  reported  a  mean  time  from  initial  symptom  onset  to  diagnosis  of  94	  
2  and  5  years   in  adult-­onset  and  JSLE,  respectively.  The  authors  concluded  95	  
that  ‘doctors  were  reluctant  to  diagnose  SLE  in  children  because  typical  signs  96	  
and  symptoms  are  less  common  and  the  milder  manifestations  of  SLE  may  by  97	  
missed  in  a  paediatric  population’  [3].    98	  
  99	  
The  UK  JSLE  Cohort  Study  was  established   in  2006  by  the  UK  JSLE  Study  100	  
Group  (http://www.liv.ac.uk/ukjsle),  with  the  aim  of  documenting  a  prospective  101	  
cohort   of   JSLE   patients.   It   collects   detailed   information   on   demographics,  102	  
ACR  SLE  criteria  [11],  disease  activity,  medication  use  and  disease  damage  103	  
indices.   The   aim   of   the   present   study   was   to   investigate   factors   that   may  104	  
influence   the   interval   between   symptom-­onset   and   JSLE   diagnosis,   using  105	  
data  collected  by  the  UK  JSLE  Cohort  study  over  5  years.  106	  
  107	  
Patients  and  methods:  108	  
  109	  
The  general  characteristics  of  the  UK  JSLE  Cohort  Study  have  recently  been  110	  
described  [12].  In  brief,  the  study  is  organised  from  a  national  coordinating  111	  
centre  in  Liverpool  and  includes  children  and  young  people  with  onset  of  112	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JSLE  prior  to  the  age  of  17  years.  Patients  are  recruited  to  the  cohort  from  all  113	  
major  paediatric  rheumatology  and  nephrology  centres  across  the  UK.    114	  
  115	  
Written  parental  consent  /  patient  consent  or  assent  to  take  part  in  the  study  116	  
was  obtained  from  all  patients  and  families  involved  in  accordance  with  the  117	  
declaration  of  Helsinki.  The  study  has  received  ethical  approval  from  the  118	  
North  West  National  Research  Ethics  Service  Committee,  Liverpool  East,  and  119	  
is  supported  by  the  UK  Clinical  Research  Network  Study  Portfolio  (for  details,  120	  
see  http://public.ukcrn.org.uk/search/).  Patients  were  eligible  for  the  current  121	  
study  if  they  were  recruited  to  the  UK  JSLE  cohort  between  2006-­11  and  met  122	  
four  of  the  eleven  established  ACR  criteria  for  lupus  [11].  123	  
  124	  
Bespoke   a   priori   case   report   forms   collect   comprehensive   clinical   and  125	  
demographic   data   for   each   JSLE   patient.   From   clinical   experience   and  126	  
previous   studies   [2,   7,   10,   11]   we   investigated   a   number   of   variables  127	  
considered   of   potential   relevance   to   accessing   specialist   care.      These  128	  
included,   demographic   factors   (ethnicity,   gender,   age   at   presentation,  129	  
socioeconomic   status,   family   history   of   autoimmune   disease   including   SLE,  130	  
rheumatoid  arthritis,   thyroid  abnormalities,   connective   tissue  disease,   type  1  131	  
diabetes   in   a   first   degree   family   relative),   factors   associated   with   disease  132	  
severity  (presenting  features,  ACR  SLE  criteria)  and  mode  of  referral  (origin  of  133	  
referral   to   paediatric   rheumatology,   distance   from   nearest   tertiary   paediatric  134	  
rheumatology  service).  Self   reported  patient  ethnicity  was  defined  according  135	  
to   the   UK   National   Census   categorisations   [13].   The   data   of   patients   who  136	  
were  of  mixed  race  were  grouped  with  those  of  the  associated  ethnic  minority  137	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group   (e.g.   Asian   and   Asian   /   Mixed   ethnic   origin   patient   data   combined  138	  
during  analysis).  The  English   index  of  multiple  deprivation   for  2007   (derived  139	  
from  postcodes)  was  used  as  a  measure  of  small  area  deprivation  of  area  of  140	  
residence  [14].    141	  
  142	  
Time   from   symptom  onset   to   diagnosis  was   non-­normally   distributed  with   a  143	  
long  tail  of  higher  values.  Therefore,  the  data  were  log  transformed  to  give  a  144	  
broadly  normal  distribution.    Variables  correlated  with  the  log  of  time  between  145	  
symptom-­onset  and  diagnosis  were   identified  (p<0.1).  Linear  regression  was  146	  
then   used   to   identify   independent   predictors   of   access   to   care   (p<0.05).  147	  
Wilcoxon   rank-­sum  test  was  used   to  compare   the   IMD  scores  of   the  Cohort  148	  
population   in   2007,  with   that   of   the  English   population   in   2007   as   a  whole.  149	  
Data  were  expressed  as  percentages,  median,  range  and  interquartile  ranges  150	  
(IQR).   Results   were   analysed   using   SPSS   version   19   software   (SPSS,  151	  
Chicago,  IL,  USA).    152	  
  153	  
Results:  154	  
A   total   of   257   participants   were   eligible   and   their   demographic   data   are  155	  
presented  in  Table  1.  The  cohort  comprised  a  preponderance  of  females  and  156	  
wide   range   of   ethnic   diversity.   The   median   time   from   symptom   onset   to  157	  
diagnosis   is   0.4   years   (range   0.0-­14.1   years,   IQR   0.2-­1.4   years).   143/258  158	  
patients   (55%)   were   diagnosed   within   6   months   of   symptom   onset   and   a  159	  
further  32/258  patients  (12%)  were  diagnosed  within  12  months.  Referrals  to  160	  
paediatric   rheumatology   directly   from   primary   care   were   uncommon   (11%)  161	  
with   the   remainder   of   referrals   being   from   general   paediatrics   and   sub-­162	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specialists.   A   family   history   of   autoimmune   disease   in   a   first-­degree   family  163	  
relative   was   present   in   27%   of   patients.   The   median   distance   from   the  164	  
patient’s   home   to   a   tertiary   paediatric   rheumatology   centre   was   21.3   miles  165	  
(range  0.1-­154.9,   IQR  9.5-­48.6  miles).  The  JSLE  cohort  population   Index  of  166	  
Multiple   Deprivation   scores   were   found   to   be   higher   than   the   English  167	  
population  as  a  whole  (p<0.001).    168	  
  169	  
Variables   correlating   with   log   of   time   to   diagnosis,   and   identified   as  170	  
independent   predictors   of   shorter   time   to   diagnosis   are   shown   in   Table   2.  171	  
Being   Caribbean   or   Asian,   compared   to   white,   was   associated   with   a   56%  172	  
and  37%   reduction   in  geometric  mean   time   to  diagnosis   respectively.  Being  173	  
referred   to   a   paediatric   rheumatology   service   by   a   paediatrician   and   having  174	  
nephritis  at  presentation,  was  also  associated  with  a  32%  and  36%  reduction  175	  
in   geometric   mean   time   to   diagnosis   respectively.   Gender,   age   at  176	  
presentation,   ACR   score,   distance   from   nearest   tertiary   paediatric  177	  
rheumatology  service,  socioeconomic  status  and  family  history  of  autoimmune  178	  




We  undertook  an  observational  study  of  a  UK  JSLE  cohort  and  demonstrated  183	  
that   ethnic   origin,   initial   source   of   referral   and   having   lupus   nephritis   at  184	  
presentation   were   strong   predictors   of   reduced   interval   to   establishing   a  185	  
diagnosis.   In   contrast   to   what   might   have   been   anticipated   from   clinical  186	  
practice  and  previous  studies  [2,  3,  5,  10],  gender,  age  at  presentation,  ACR  187	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score,   distance   from   nearest   tertiary   paediatric   rheumatology   service,  188	  
socioeconomic   status   and   family   history   of   autoimmune   disease   were   not  189	  
found  to  be  significant  predictors  of  access  to  care.    190	  
  191	  
The   baseline   demographic   and   clinical   data   from   this   large,   national,  192	  
multicentre   collaborative   UK   JSLE   Cohort   Study   highlight   the   considerable  193	  
variation   in   time   taken   to   achieve   a   diagnosis   of   JSLE   within   the   UK,   with  194	  
some   patients   being   diagnosed   quickly,   and   others   facing   major   delays.  195	  
These  data  suggest  that  multiple  referrals  occur  within  secondary  and  tertiary  196	  
care   before   accessing   paediatric   rheumatology   care,   providing   important  197	  
insights  into  potential  factors  that  may  contribute  to  the  wide  variation  in  time  198	  
taken  to  achieve  a  diagnosis.  The  importance  of  early  diagnosis  is  highlighted  199	  
by  clinical  outcome  data  for   lupus  nephritis  [15],  and  also  by  the  observation  200	  
that   patients   with   JSLE   from   the   US   who   lack   comprehensive   medical  201	  
insurance   and   have   reduced   access   to   care,   have   higher   rates   of  202	  
complications  [10].    203	  
  204	  
Previous  studies  exploring  access  to  care  in  JIA  suggest  that  the  explanation  205	  
for  delay  in  referral  is  multi-­factorial,  with  the  experience  and  knowledge  of  the  206	  
healthcare  professionals  to  whom  the  family  present  being  paramount,  as  well  207	  
as  social,  cultural,  organisational  and  health  network  related  factors  [2,  3,  16].  208	  
General  practitioners  and  paediatric  trainees  have  been  shown  to  display  poor  209	  
confidence   in   paediatric   musculoskeletal   assessment   [17]   and   a   lack   of  210	  
awareness  of  rheumatic  diseases  in  children  and  young  people.  In  response  211	  
to   this,   innovative   educational   resources   have   been   developed   to   improve  212	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paediatric   musculoskeletal   examination   skills   [18].   Adaptation   of   existing  213	  
resources   or   development   of   JSLE   specific   resources   is   required,   as   the  214	  
increased   incidence   of   internal   organ   involvement   in   JSLE   may   negatively  215	  
influence  the  ‘visibility’  of  disease  [12,  19].  216	  
  217	  
In  adult  SLE  it  is  known  that  socio-­demographic  disparities  exist  in  relation  to  218	  
both  initial  and  on-­going  access  to  healthcare,  resulting  in  differences  in  long-­219	  
term  outcomes,  hospitalisations,  morbidity  and  ultimately  mortality  [10].  These  220	  
observation   have   mainly   come   from   American   studies,   and   emphasise   the  221	  
contribution   of   ethnicity,   gender,   education,   adherence,   social   support,  222	  
socioeconomic   status,   mode   of   healthcare   delivery,   medical   insurance   type  223	  
and   geographical   location   of   appropriate   healthcare,   as   determinants   of  224	  
access   to   care.   The   relative   influence   of   individual   factors   is   difficult   to  225	  
disentangle,  as  many  social  determinants  of  health  frequently  co-­exist.    226	  
  227	  
Specific  factors  such  as  distance  to  a  paediatric  rheumatology  centre  may  be  228	  
more  of  an  issue  in  a  large  county  like  the  US,  and  determinants  of  access  to  229	  
care  may   also   differ   according   to   the   populations’   basic   demographics   and  230	  
healthcare  system  structure.  In  terms  of  access  to  and  use  of  care  in  chronic  231	  
diseases,   the   literature   suggests   a   different   picture   in   adults   and   children,  232	  
whereby  care  tends  to  be  more  equitably  delivered  to  children  [20].  In  the  UK  233	  
National  Health  System  (NHS),  where  care   is  universally   free  at   the  point  of  234	  
access,  some  studies  have  suggested  equality  of  access   to  secondary  care  235	  
services   in   children   by   socioeconomic   status   [21],   whereas   others   have  236	  
demonstrated   inequity   in   the   utilisation   of   specialist   services   in   relation   to  237	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socio-­economic  status  (e.g.  in  eye-­care  services)  [22].  A  further  study  of  cystic  238	  
fibrosis  care  suggested  that  UK  clinicians  consider  deprivation  status  as  well  239	  
as   diseases   status   when   making   decisions   about   treatments,   potentially  240	  
mitigating  some  of  the  effects  of  social  disadvantage  on  health  outcomes  [23].    241	  
  242	  
A  qualitative  study  looking  at  the  perceptions  of  healthcare  provision  in  adults  243	  
with  SLE   in   the  UK  has  described   four  main   themes  which   relate   to  patient  244	  
experiences;;   ‘searching   for   an   answer’,   ‘nobody   can   understand’,   ‘are   they  245	  
really   listening’  and   ‘joining   the  dots’.  These   themes  highlight   the  diagnostic  246	  
difficulties  faced  by  adults  with  SLE,  the  lack  of  basic  understanding  of  SLE  by  247	  
GP’s   and   healthcare   providers,   and   the   need   for   cohesive   healthcare   [24].  248	  
These  experiences  may  resonate  with  those  of  young  people  with  JSLE,  but  249	  
in   view   of   the   known   significant   differences   between   childhood   and   adult  250	  
onset  SLE   [3-­5,  12],   it   is   likely   that  additional  and  distinct   factors  may  be  of  251	  
importance.    252	  
  253	  
Strengths   of   this   study   include   the   large,   nationally   representative,  254	  
prospectively  collected  data,  however,  the  limitations  must  be  acknowledged.  255	  
The  UK  JSLE  Cohort  Study  was  not  specifically  designed  to  explore  barriers  256	  
and  drivers  of  access  to  care,  and  does  not  collect  detailed  data  on  the  time-­257	  
period   prior   to   diagnosis.   Clearly   there   is   a   potential   bias   towards   patients  258	  
seen  at   large   tertiary   centres   connected   to   the  UK  JSLE  Cohort   study,  with  259	  
data   lacking   from   patients   who   have   been   managed   in   other   paediatric  260	  
centres   or   in   adult   healthcare.   The   number   of   patients   described   is   smaller  261	  
than  in  some  adult  lupus  cohorts  [10],  and  consequently  the  study  may  not  be  262	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adequately   powered   to   detect   the   influence   of   all   previously   described  263	  
determinants  of  access  to  care.  Other  potentially  important  covariates  such  as  264	  
age,  occupation,  level  of  educational  attainment,  marital  status,  social  support  265	  
of  parents  /  carers  and  existing  knowledge  of  JSLE  are  currently  not  collected  266	  
by  the  UK  JSLE  cohort  study,  but  may  also  bear  influence  on  access  to  care.  267	  
Our  study  provides   insight  and  a  basis  on  which   to  design   further  studies   to  268	  
gain   a   more   in-­depth   understanding   of   the   barriers   and   facilitators   to  269	  
appropriate  care  and  achieving  a  diagnosis  in  JSLE.    270	  
  271	  
In   conclusion,   timely   access   to   comprehensive   specialist   care   is   crucial   in  272	  
JSLE.   The   UK   JSLE   Cohort   Study   data   demonstrates   that   there   is  273	  
considerable  variation  in  time  taken  to  achieve  a  diagnosis  of  JSLE  within  the  274	  
UK.  Future  studies  combining  qualitative  and  quantitative  methodologies  are  275	  
warranted  to  provide  important  insights  into  the  experiences  and  challenges  of  276	  
achieving  a  diagnosis  of  JSLE.  Recognition  of  such  barriers  and  facilitators  to  277	  
appropriate  care  will  inform  recommendations  for  interventions  and  strategies  278	  
to   improve   access   to   and   delivery   of   specialist   care   in   JSLE   across   the  279	  
boundaries  of  paediatric,  adolescent  and  adult  care  within  clinical  networks.    280	  
  281	  
Key  messages  282	  
1.   Length  of  time  to  achieve  a  diagnosis  of  JSLE  varies  widely.  283	  
2.   These   data   suggest   that   JSLE   patients   experience   multiple   referrals  284	  
before  accessing  paediatric  rheumatology  care.  285	  
  286	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